|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar
|
|
2
|
No authors listed. Erratum: Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
70:3132020. View Article : Google Scholar
|
|
3
|
Bae JM, Choi YY, Kim DS, Lee JH, Jang HS,
Lee JH, Kim H, Oh BH, Roh MR, Nam KA and Chung KY: Metastatic
melanomas of unknown primary show better prognosis than those of
known primary: A systematic review and meta-analysis of
observational studies. J Am Acad Dermatol. 72:59–70. 2015.
View Article : Google Scholar
|
|
4
|
Swetter SM, Thompson JA, Albertini MR,
Barker CA, Baumgartner J, Boland G, Chmielowski B, DiMaio D, Durham
A, Fields RC, et al: NCCN guidelines® insights:
Melanoma: Cutaneous, version 2.2021. J Natl Compr Canc Netw.
19:364–376. 2021. View Article : Google Scholar
|
|
5
|
Strojan P: Role of radiotherapy in
melanoma management. Radiol Oncol. 44:1–12. 2010. View Article : Google Scholar
|
|
6
|
Turley SJ, Cremasco V and Astarita JL:
Immunological hallmarks of stromal cells in the tumour
microenvironment. Nat Rev Immunol. 15:669–682. 2015. View Article : Google Scholar
|
|
7
|
Twyman-Saint Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015. View Article : Google Scholar
|
|
8
|
Mohamad O, Diaz de Leon A, Schroeder S,
Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB,
Laine A, et al: Safety and efficacy of concurrent immune checkpoint
inhibitors and hypofractionated body radiotherapy. Oncoimmunology.
7:e14401682018. View Article : Google Scholar
|
|
9
|
Yin L, Xue J, Li R, Zhou L, Deng L, Chen
L, Zhang Y, Li Y, Zhang X, Xiu W, et al: Effect of low-dose
radiation therapy on abscopal responses to hypofractionated
radiation therapy and anti-PD1 in mice and patients with non-small
cell lung cancer. Int J Radiat Oncol Biol Phys. 108:212–224. 2020.
View Article : Google Scholar
|
|
10
|
Gabani P, Robinson CG, Ansstas G, Johanns
TM and Huang J: Use of extracranial radiation therapy in metastatic
melanoma patients receiving immunotherapy. Radiother Oncol.
127:310–317. 2018. View Article : Google Scholar
|
|
11
|
Welsh JW, Tang C, de Groot P, Naing A,
Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V,
Chang JY, et al: Phase II trial of ipilimumab with stereotactic
radiation therapy for metastatic disease: Outcomes, toxicities, and
low-dose radiation-related abscopal responses. Cancer Immunol Res.
7:1903–1909. 2019. View Article : Google Scholar
|
|
12
|
Funck-Brentano E, Baghad B, Fort M,
Aouidad I, Roger A, Beauchet A, Otmezguine Y, Blom A, Longvert C,
Boru B and Saiag P: Efficacy of late concurrent hypofractionated
radiotherapy in advanced melanoma patients failing anti-PD-1
monotherapy. Int J Cancer. 147:1707–1714. 2020. View Article : Google Scholar
|
|
13
|
Theelen WSMW, Chen D, Verma V, Hobbs BP,
Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot
PM, et al: Pembrolizumab with or without radiotherapy for
metastatic non-small-cell lung cancer: A pooled analysis of two
randomised trials. Lancet Respir Med. 9:467–475. 2021. View Article : Google Scholar
|
|
14
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015. View Article : Google Scholar
|
|
15
|
Dummer R, Hauschild A, Santinami M,
Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J,
Nyakas M, Dutriaux C, et al: Five-year analysis of adjuvant
dabrafenib plus trametinib in stage III melanoma. N Engl J Med.
383:1139–1148. 2020. View Article : Google Scholar
|
|
16
|
Gershenwald JE, Scolyer RA, Hess KR,
Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM,
McArthur GA, et al: Melanoma staging: Evidence-based changes in the
American joint committee on cancer eighth edition cancer staging
manual. CA Cancer J Clin. 67:472–492. 2017. View Article : Google Scholar
|
|
17
|
Cook J: Surgical margins for resection of
primary cutaneous melanoma. Clin Dermatol. 22:228–233. 2004.
View Article : Google Scholar
|
|
18
|
Eriksson H, Frohm-Nilsson M, Järås J,
Kanter-Lewensohn L, Kjellman P, Månsson-Brahme E, Vassilaki I and
Hansson J: Prognostic factors in localized invasive primary
cutaneous malignant melanoma: Results of a large population-based
study. Br J Dermatol. 172:175–186. 2015. View Article : Google Scholar
|
|
19
|
Tarhini AA: Immunotherapy of melanoma.
Curr Mol Pharmacol. 9:196–207. 2016. View Article : Google Scholar
|
|
20
|
Alexandrov LB, Kim J, Haradhvala NJ, Huang
MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom
EN, et al: The repertoire of mutational signatures in human cancer.
Nature. 578:94–101. 2020. View Article : Google Scholar
|
|
21
|
Sharma P, Hu-Lieskovan S, Wargo JA and
Ribas A: Primary, adaptive, and acquired resistance to cancer
immunotherapy. Cell. 168:707–723. 2017. View Article : Google Scholar
|
|
22
|
Jenkins RW, Barbie DA and Flaherty KT:
Mechanisms of resistance to immune checkpoint inhibitors. Br J
Cancer. 118:9–16. 2018. View Article : Google Scholar
|
|
23
|
Burnette BC, Liang H, Lee Y, Chlewicki L,
Khodarev NN, Weichselbaum RR, Fu YX and Auh SL: The efficacy of
radiotherapy relies upon induction of type I interferon-dependent
innate and adaptive immunity. Cancer Res. 71:2488–2496. 2011.
View Article : Google Scholar
|
|
24
|
Kim KW, Jeong JU, Lee KH, Uong TNT, Rhee
JH, Ahn SJ, Kim SK, Cho D, Quang Nguyen HP, Pham CT and Yoon MS:
Combined NK cell therapy and radiation therapy exhibit long-term
therapeutic and antimetastatic effects in a human triple negative
breast cancer model. Int J Radiat Oncol Biol Phys. 108:115–125.
2020. View Article : Google Scholar
|
|
25
|
Ji RR, Chasalow SD, Wang L, Hamid O,
Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M,
Siemers NO, et al: An immune-active tumor microenvironment favors
clinical response to ipilimumab. Cancer Immunol Immunother.
61:1019–1031. 2012. View Article : Google Scholar
|
|
26
|
Shaverdian N, Lisberg AE, Bornazyan K,
Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P:
Previous radiotherapy and the clinical activity and toxicity of
pembrolizumab in the treatment of non-small-cell lung cancer: A
secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol.
18:895–903. 2017. View Article : Google Scholar
|
|
27
|
Liniker E, Menzies AM, Kong BY, Cooper A,
Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, et
al: Activity and safety of radiotherapy with anti-PD-1 drug therapy
in patients with metastatic melanoma. Oncoimmunology.
5:e12147882016. View Article : Google Scholar
|
|
28
|
Klug F, Prakash H, Huber PE, Seibel T,
Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et
al: Low-dose irradiation programs macrophage differentiation to an
iNOS+/M1 phenotype that orchestrates effective T cell
immunotherapy. Cancer Cell. 24:589–602. 2013. View Article : Google Scholar
|
|
29
|
Menon H, Ramapriyan R, Cushman TR, Verma
V, Kim HH, Schoenhals JE, Atalar C, Selek U, Chun SG, Chang JY, et
al: Role of radiation therapy in modulation of the tumor stroma and
microenvironment. Front Immunol. 10:1932019. View Article : Google Scholar
|
|
30
|
Sezen D, Patel RR, Tang C, Onstad M,
Nagarajan P, Patel SP, Welsh JW and Lin LL: Immunotherapy combined
with high- and low-dose radiation to all sites leads to complete
clearance of disease in a patient with metastatic vaginal melanoma.
Gynecol Oncol. 161:645–652. 2021. View Article : Google Scholar
|
|
31
|
Lee VHF: Case sharing of a patient
re-challenged with afatinib for EGFR-mutated advanced non-small
cell lung cancer. Asia Pac J Clin Oncol. 14 (Suppl 1):S4–S6. 2018.
View Article : Google Scholar
|
|
32
|
Schreuer M, Jansen Y, Planken S, Chevolet
I, Seremet T, Kruse V and Neyns B: Combination of dabrafenib plus
trametinib for BRAF and MEK inhibitor pretreated patients with
advanced BRAFV600-mutant melanoma: An open-label, single
arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 18:464–472.
2017. View Article : Google Scholar
|
